Economics of Beta-Cell Replacement Therapy
Purpose of Review: Type 1 diabetes impacts 1.3 million people in the USA with a total direct lifetime medical cost of $133.7 billion. Management requires a mix of daily exogenous insulin administration and frequent glucose monitoring. Decision-making by the individual can be burdensome. Recent Findi...
Main Authors: | Bandeiras, Cátia, Hwa, Albert J., Cabral, Joaquim M. S., Ferreira, Frederico Castelo, Finkelstein, Stan Neil, Gabbay, Robert A. |
---|---|
Other Authors: | Massachusetts Institute of Technology. Institute for Data, Systems, and Society |
Format: | Article |
Language: | English |
Published: |
Springer Science and Business Media LLC
2020
|
Online Access: | https://hdl.handle.net/1721.1/128519 |
Similar Items
-
Bioprocess Economic Modeling: Decision Support Tools for the Development of Stem Cell Therapy Products
by: William O. S. Salvador, et al.
Published: (2022-12-01) -
Magnetic Field Dynamic Strategies for the Improved Control of the Angiogenic Effect of Mesenchymal Stromal Cells
by: Ana C. Manjua, et al.
Published: (2021-06-01) -
Engineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells
by: D.C. Oran, et al.
Published: (2019-03-01) -
Predicting intensive care unit admission among patients presenting to the emergency department using machine learning and natural language processing
by: Finkelstein, Stan Neil
Published: (2020) -
Renal replacement therapy does have impact on beta-lactam clearance
by: Zhenwei Yu
Published: (2023-06-01)